|
|
Post by patten1962 on Jun 12, 2016 18:21:22 GMT -5
Mahalo Q, but I rather think the "good stuff" will happen much past July. This is still in its embryonic stages and will take time. Nonetheless, I like the recent good news to support future sales. I'm long for a reason and July 2016 is not included as any type of benchmark for me at least, as much as I'd like to be wrong about that. To borrow and slightly alter a sports cliche, we're 6 months away from being 6 months away imho Quoting Confucius. " a journey of Ten Thousand Miles begins with the first step" This is good news. Will not make sp go to $10. What it will do is bring awareness to the Medical Community! |
|
|
|
Post by anderson on Jun 12, 2016 18:45:10 GMT -5
Very impressive. Now that's what I'm talking about, and the way the booth looks at the ADA; well, who cares? It's all about this my fellow investors; how MNKD spreads this news far/wide, and how our new sales reps take this into the field. Just awesome! I like this new leadership that's sailing HMS MNKD! Aloha. Kauai - Yes. Very good press release, and nicely timed with JDRF. Communications though will be very important - they will need to do a good job advertising, etc to medical community and patients. The same folks who run booths usually run the other slate of comms - so I'm just hoping this was a case of they went cheap on the booth due to the extremely tight budget this spring, and went the DYI route this round, but the rest from July on is outsourced to that agency - who hopefully knows what they are doing. Sorry. Not trying to be a wet towel here - but we've already seen the result of this done wrong (aka: SNY) I'm going to give Mike benefit of doubt and go with that thought above .... that we'll start seeing the good stuff starting July. The question is did they really have time to design a good booth. They have been working a lot of issues and they secured the booth late, so they probably just ran out of time to redesign for a larger booth. |
|
|
|
Post by blu2waz on Jun 12, 2016 19:10:02 GMT -5
Advertise or not Mannkind has to warn that the insulin is out of the body much faster and could be the cause of a hypoglycemic episode if label instructions were not deviated from. To not warn users would be actionable and would be reckless behavior. Morally they are obligated to inform that Afrezza is so much better than the FDA would allow to be published that an unforeseen problem can occur due to the stupidity/corruption(you choose the word) of the powers that be. Check?
|
|
|
|
Post by patten1962 on Jun 12, 2016 19:45:21 GMT -5
To be honest, would be kind of cool to see a little bump in TelAviv!  |
|
|
|
Post by sportsrancho on Jun 12, 2016 19:48:50 GMT -5
|
|
|
|
Post by uvula on Jun 12, 2016 20:00:32 GMT -5
Advertise or not Mannkind has to warn that the insulin is out of the body much faster and could be the cause of a hypoglycemic episode if label instructions were not deviated from. To not warn users would be actionable and would be reckless behavior. Morally they are obligated to inform that Afrezza is so much better than the FDA would allow to be published that an unforeseen problem can occur due to the stupidity/corruption(you choose the word) of the powers that be. Check? Do you know the difference between hypo and hyper? |
|
|
|
Post by capnbob on Jun 12, 2016 20:37:42 GMT -5
The problem is that even if the data is accurate and the claims are true, and even if MNKD could use it all to effect a label change, it would still be faced with third party reimbursement -- the underlying core problem. In assessing reimbursement policy, insurers don't care what a drug does as long as the clinical outcomes indicate it could reduce their costs. Consequently, there remains a serious need for a trial to demonstrate that afrezza improves those outcomes -- more specifically, does a better job of reducing A1C.
|
|
|
|
Post by cm5 on Jun 12, 2016 20:49:27 GMT -5
Re: stated concerns "proving" HgbA1C, see following. Also read resources about post prandial blood sugar levels and consequent HcbA1C. And, undoubtedly, given below, studies are underway.  cm5 Jun 4, 2016 8:48:59 GMT -4 cm5 said: More: Mannkind Patents 8,258,095Again, critical time to bring attention/focus to the below:
Method of controlling glycemia by ultrarapid acting insulin without adjusting an insulin dose for meal content
www.google.com/patents/US8258095B2 |
|
|
|
Post by peppy on Jun 12, 2016 21:40:54 GMT -5
To be honest, would be kind of cool to see a little bump in TelAviv! look at japan and china markets tonight. Europe and usa to follow.
|
|
|
|
Post by babaoriley on Jun 13, 2016 1:00:25 GMT -5
Advertise or not Mannkind has to warn that the insulin is out of the body much faster and could be the cause of a hypoglycemic episode if label instructions were not deviated from. To not warn users would be actionable and would be reckless behavior. Morally they are obligated to inform that Afrezza is so much better than the FDA would allow to be published that an unforeseen problem can occur due to the stupidity/corruption(you choose the word) of the powers that be. Check? Do you know the difference between hypo and hyper? I do!! I do!! "Hyper" that's if you're more cool than the guy your comparing yourself with, like, "I'm way hyper than Matt Pfeffer." "Hypo," those are those big animals in jungle rivers, with the huge jaws, you can see them on the Jungle Cruise in Disneyland. How'd I do? How'd I do?  |
|
|
|
Post by mnholdem on Jun 13, 2016 1:38:25 GMT -5
Baba is getting too hyper...somebody get a hypo, please!  |
|
